Shunichi Toki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shunichi Toki has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Koichi Sairyo
Department of Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
6 shared publicationsToshihiko Nishisho
Department of Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
3 shared publications- Toshihiko Nishisho
Department of Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan
3 shared publications Kazuta Yamashita
Tokushima Univ, Dept Orthoped, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan
2 shared publications- Koichi Sairyo
Department of Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School
2 shared publications - Makoto Takeuchi
Department of Orthopedics, Tokushima University Graduate School, Institute of Biomedical Sciences, Tokushima, Japan
2 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Electronic patient-reported outcome monitoring system for sarcoma patients undergoing drug treatment: a development and feasibility study
Symptom and quality of life monitoring using electronic patient-reported outcomes has been widely adopted for common cancers. However, there are few such s
- 19 May 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessElectronic patient-reported outcome monitoring system for sarcoma patients undergoing drug treatment: a development and feasibility study
Symptom and quality of life monitoring using electronic patient-reported outcomes has been widely adopted for common cancers. However, there are few such s
- Open Access
- 24 March 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (6) , e70770
Blue Light Emitting Diode Suppresses Sarcoma Cell Proliferation via the Endogenous Apoptotic Pathway Without Damaging Normal Cells
Background: The development of novel therapies for sarcoma is urgently required because most sarcomas are refractory to adjuvant therapy and the treatment options are limited. Although antitumor effects of blue light (BL) have been reported for several malignant tumors, its impact on various sarcomas remains unknown. In this study, we examined the antitumor effects of BL on several kinds of bone and soft tissue sarcomas.Methods: We used human osteosarcoma, undifferentiated pleomorphic sarcoma, liposarcoma, and myxofibrosarcoma cell lines, as well as a human dermal fibroblast cell line as normal cells. We continuously irradiated these cells with BL in an incubator.Results: BL inhibited cell proliferation in sarcoma cells, but hardly affected normal cells. BL increased intracellular reactive oxygen species (ROS) levels in sarcoma cells, but not in normal cells. Interestingly, oxidative stress occurred after BL irradiation in both sarcoma and normal cells. In addition, apoptosis, autophagy, and mitochondrial dysfunction, which were induced by ROS, occurred in sarcoma cells. In undifferentiated pleomorphic sarcoma cells, BL caused cell death through activation of the endogenous apoptotic pathway, and autophagy counteracted the apoptosis.Conclusion: Our results indicate that BL might specifically kill sarcoma cells without injuring normal cells and may become a new treatment option for sarcoma.
- 24 March 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (6) , e70770
Open AccessBlue Light Emitting Diode Suppresses Sarcoma Cell Proliferation via the Endogenous Apoptotic Pathway Without Damaging Normal Cells
Background: The development of novel therapies for sarcoma is urgently required because most sarcomas are refractory to adjuvant therapy and the treatment options are limited. Although antitumor effects of blue light (BL) have been reported for several malignant tumors, its impact on various sarcomas remains unknown. In this study, we examined the antitumor effects of BL on several kinds of bone and soft tissue sarcomas.Methods: We used human osteosarcoma, undifferentiated pleomorphic sarcoma, liposarcoma, and myxofibrosarcoma cell lines, as well as a human dermal fibroblast cell line as normal cells. We continuously irradiated these cells with BL in an incubator.Results: BL inhibited cell proliferation in sarcoma cells, but hardly affected normal cells. BL increased intracellular reactive oxygen species (ROS) levels in sarcoma cells, but not in normal cells. Interestingly, oxidative stress occurred after BL irradiation in both sarcoma and normal cells. In addition, apoptosis, autophagy, and mitochondrial dysfunction, which were induced by ROS, occurred in sarcoma cells. In undifferentiated pleomorphic sarcoma cells, BL caused cell death through activation of the endogenous apoptotic pathway, and autophagy counteracted the apoptosis.Conclusion: Our results indicate that BL might specifically kill sarcoma cells without injuring normal cells and may become a new treatment option for sarcoma.
- Open Access
- 1 July 2023
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 108, 108456
Atypical femoral fracture in a multiple myeloma patient undergoing treatment with denosumab: A case report and literature review
Denosumab is a new standard treatment for bone disease caused by multiple myeloma. There are a few reports of atypical femoral fracture in patients with multiple myeloma, all of which were associated with long-term use of bisphosphonate. Here, we report the first case of denosumab-induced atypical femoral fracture in a patient with multiple myeloma. A 71-year-old woman with multiple myeloma developed dull pain in her right thigh 8 months after restarting high-dose denosumab following its initial administration for 4 months and subsequent withdrawal for 2 years. Fourteen months later, complete atypical femoral fracture occurred. Osteosynthesis was achieved using an intramedullary nail and she was switched to oral bisphosphonate 7 months after cessation of denosumab. There was no exacerbation of the multiple myeloma. Bone union was achieved and she recovered to her pre-injury level of activities. The oncological outcome was alive with disease at 2 years after surgery. Prodromal symptoms such as thigh pain and radiographical finding of thickening of the lateral cortex in the subtrochanteric region of the femur were attributed to denosumab-induced atypical femoral fracture in the case. A unique aspect of this case worth highlighting is that the fracture occurred after short-term denosumab use. This may be associated with multiple myeloma or other medication including dexamethasone and cyclophosphamide. Atypical femoral fracture may occur in patients with multiple myeloma who receive denosumab, even for a short period. Attending physicians should be cognizant of the early symptoms and signs of this fracture.
- 1 July 2023
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 108, 108456
Open AccessAtypical femoral fracture in a multiple myeloma patient undergoing treatment with denosumab: A case report and literature review
Denosumab is a new standard treatment for bone disease caused by multiple myeloma. There are a few reports of atypical femoral fracture in patients with multiple myeloma, all of which were associated with long-term use of bisphosphonate. Here, we report the first case of denosumab-induced atypical femoral fracture in a patient with multiple myeloma. A 71-year-old woman with multiple myeloma developed dull pain in her right thigh 8 months after restarting high-dose denosumab following its initial administration for 4 months and subsequent withdrawal for 2 years. Fourteen months later, complete atypical femoral fracture occurred. Osteosynthesis was achieved using an intramedullary nail and she was switched to oral bisphosphonate 7 months after cessation of denosumab. There was no exacerbation of the multiple myeloma. Bone union was achieved and she recovered to her pre-injury level of activities. The oncological outcome was alive with disease at 2 years after surgery. Prodromal symptoms such as thigh pain and radiographical finding of thickening of the lateral cortex in the subtrochanteric region of the femur were attributed to denosumab-induced atypical femoral fracture in the case. A unique aspect of this case worth highlighting is that the fracture occurred after short-term denosumab use. This may be associated with multiple myeloma or other medication including dexamethasone and cyclophosphamide. Atypical femoral fracture may occur in patients with multiple myeloma who receive denosumab, even for a short period. Attending physicians should be cognizant of the early symptoms and signs of this fracture.
- Open Access
- 1 February 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (8) , 9668-9683
Blue light induces apoptosis and autophagy by promoting ROS‐mediated mitochondrial dysfunction in synovial sarcoma
Background: Synovial sarcoma (SS) has limited treatment options and there is an urgent need to develop a novel therapeutic strategy to treat SS. Blue light (BL) has been shown to inhibit the growth of several cancer cells. However, the efficacy of BL in soft tissue sarcomas such as SS has not been demonstrated, and the detailed mechanism underlying the antitumor activity of BL is not fully understood. In this study, we investigated the antitumor effect of BL on SS.Methods: Human SS cell lines were continuously irradiated with BL using light‐emitting diodes (LEDs) in an incubator for in vitro analysis. The chicken chorioallantoic membrane (CAM) tumors and xenograft tumors in mice were subjected to daily BL irradiation with LEDs.Results: BL caused growth inhibition of SS cells and histological changes in CAM tumors. BL also suppressed the migration and invasion abilities of SS cells. The type of cell death in SS cells was revealed to be apoptosis. Furthermore, BL induced excessive production of reactive oxygen species (ROS) in mitochondria, resulting in oxidative stress and malfunctioned mitochondria. Reducing the production of ROS using N‐acetylcysteine (NAC), a ROS scavenger, attenuated the inhibitory effect of BL on SS cells and mitochondrial dysfunction. In addition, BL induced autophagy, which was suppressed by the administration of NAC. The autophagy inhibitor of 3‐methyladenine and small interfering RNA against the autophagy marker light chain 3B facilitated apoptotic cell death. Moreover, BL suppressed tumor growth in a mouse xenograft model.Conclusion: Taken together, our results revealed that BL induced apoptosis via the ROS‐mitochondrial signaling pathway, and autophagy was activated in response to the production of ROS, which protected SS cells from apoptosis. Therefore, BL is a promising candidate for the development of an antitumor therapeutic strategy targeting SS.
- 1 February 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (8) , 9668-9683
Open AccessBlue light induces apoptosis and autophagy by promoting ROS‐mediated mitochondrial dysfunction in synovial sarcoma
Background: Synovial sarcoma (SS) has limited treatment options and there is an urgent need to develop a novel therapeutic strategy to treat SS. Blue light (BL) has been shown to inhibit the growth of several cancer cells. However, the efficacy of BL in soft tissue sarcomas such as SS has not been demonstrated, and the detailed mechanism underlying the antitumor activity of BL is not fully understood. In this study, we investigated the antitumor effect of BL on SS.Methods: Human SS cell lines were continuously irradiated with BL using light‐emitting diodes (LEDs) in an incubator for in vitro analysis. The chicken chorioallantoic membrane (CAM) tumors and xenograft tumors in mice were subjected to daily BL irradiation with LEDs.Results: BL caused growth inhibition of SS cells and histological changes in CAM tumors. BL also suppressed the migration and invasion abilities of SS cells. The type of cell death in SS cells was revealed to be apoptosis. Furthermore, BL induced excessive production of reactive oxygen species (ROS) in mitochondria, resulting in oxidative stress and malfunctioned mitochondria. Reducing the production of ROS using N‐acetylcysteine (NAC), a ROS scavenger, attenuated the inhibitory effect of BL on SS cells and mitochondrial dysfunction. In addition, BL induced autophagy, which was suppressed by the administration of NAC. The autophagy inhibitor of 3‐methyladenine and small interfering RNA against the autophagy marker light chain 3B facilitated apoptotic cell death. Moreover, BL suppressed tumor growth in a mouse xenograft model.Conclusion: Taken together, our results revealed that BL induced apoptosis via the ROS‐mitochondrial signaling pathway, and autophagy was activated in response to the production of ROS, which protected SS cells from apoptosis. Therefore, BL is a promising candidate for the development of an antitumor therapeutic strategy targeting SS.
- Open Access
- 1 March 2022
- Published by Elsevier in Journal of Orthopaedic Science
- Vol. 27 (2) , 448-455
Image-guided core needle biopsy for musculoskeletal lesions
- 1 March 2022
- Published by Elsevier in Journal of Orthopaedic Science
- Vol. 27 (2) , 448-455
Open AccessImage-guided core needle biopsy for musculoskeletal lesions
- Open Access
- 1 March 2021
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 23
Extradural ancient schwannoma of the spine: 2 cases and literature review
- 1 March 2021
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 23
Open AccessExtradural ancient schwannoma of the spine: 2 cases and literature review
- Open Access
- 23 May 2019
- Published by Wiley in Case Reports in Orthopedics
- Vol. 2019, 1-5
A Rare Case of Acute-Onset Spastic Quadriparesis Caused by a Chondroma of the Cervical Spine
Chondromas are benign cartilaginous tumors that occur very rarely in the spine. Moreover, chondromas of the extraskeletal origin are also very rare. In this case report, we describe an extremely rare case of chondroma arising from the ligamentum flavum in the cervical spine. A 67-year-old man presented to our clinic with acute-onset spastic quadriparesis. We performed emergent magnetic resonance imaging and found an epidural mass in the right ligamentum flavum at C4-C5. The acute-onset presentation was suspicious for intraligamentous hematoma in the ligamentum flavum at this level. We performed emergency decompression surgery and en bloc removal of the epidural mass with the right C4 and C5 lamina. The lesion had the appearance of cartilaginous tissue rather than hematoma. Based on the histological investigation, the final diagnosis was intraligamentous chondroma of the cervical spine. The quadriparesis improved postoperatively, as did the results of manual muscle testing in the affected area, and he was able to resume walking independently with a cane. At the one-year follow-up, the manual muscle testing results were almost normal. Surgeons should keep in mind the possibility of benign tumors including chondroma of the cervical spine when a patient presents with acute-onset quadriparesis.
- 23 May 2019
- Published by Wiley in Case Reports in Orthopedics
- Vol. 2019, 1-5
Open AccessA Rare Case of Acute-Onset Spastic Quadriparesis Caused by a Chondroma of the Cervical Spine
Chondromas are benign cartilaginous tumors that occur very rarely in the spine. Moreover, chondromas of the extraskeletal origin are also very rare. In this case report, we describe an extremely rare case of chondroma arising from the ligamentum flavum in the cervical spine. A 67-year-old man presented to our clinic with acute-onset spastic quadriparesis. We performed emergent magnetic resonance imaging and found an epidural mass in the right ligamentum flavum at C4-C5. The acute-onset presentation was suspicious for intraligamentous hematoma in the ligamentum flavum at this level. We performed emergency decompression surgery and en bloc removal of the epidural mass with the right C4 and C5 lamina. The lesion had the appearance of cartilaginous tissue rather than hematoma. Based on the histological investigation, the final diagnosis was intraligamentous chondroma of the cervical spine. The quadriparesis improved postoperatively, as did the results of manual muscle testing in the affected area, and he was able to resume walking independently with a cane. At the one-year follow-up, the manual muscle testing results were almost normal. Surgeons should keep in mind the possibility of benign tumors including chondroma of the cervical spine when a patient presents with acute-onset quadriparesis.
- Open Access
- 1 January 2017
- Published by Wiley in Case Reports in Orthopedics
- Vol. 2017 (1) , 3025084
Atypical Lipomatous Tumor/Well‐Differentiated Liposarcoma Developed in a Patient with Progressive Muscular Dystrophy: A Case Report and Review of the Literature
Background. Atypical lipomatous tumor/well‐differentiated liposarcoma (ALT/WDLS) is an intermediate or locally aggressive form of adipocytic soft tissue sarcoma. Muscular dystrophy (MD) is characterized by progressive muscle atrophy and its replacement by adipose and fibrous tissue. Recently, some authors have reported that MD genes are related to neoplastic formation, but there have been no detailed clinical reports of ALT associated with MD. Case Presentation. A 73‐year‐old woman with a diagnosis of limb‐girdle MD visited our department for recurrence of a huge tumor in her left thigh. She had undergone resection of a lipoma at the same site more than 20 years earlier. Imaging studies revealed a lipomatous tumor in her left thigh. We performed marginal resection including the adjacent muscles. Histological diagnosis was atypical lipomatous tumor. The postoperative course was uneventful, with no recurrence at 36 months of follow‐up. Conclusion. We encountered a huge atypical tumor in a patient with MD. This is the first detailed report to describe an association between ALT and MD. We hypothesize that degenerative changes occurring in adipose tissue during muscle atrophy can cause lipomatous neoplasms and moreover that the mutation of MD‐related genes may lead to the proliferation of tumor cells or to malignancy.
- 1 January 2017
- Published by Wiley in Case Reports in Orthopedics
- Vol. 2017 (1) , 3025084
Open AccessAtypical Lipomatous Tumor/Well‐Differentiated Liposarcoma Developed in a Patient with Progressive Muscular Dystrophy: A Case Report and Review of the Literature
Background. Atypical lipomatous tumor/well‐differentiated liposarcoma (ALT/WDLS) is an intermediate or locally aggressive form of adipocytic soft tissue sarcoma. Muscular dystrophy (MD) is characterized by progressive muscle atrophy and its replacement by adipose and fibrous tissue. Recently, some authors have reported that MD genes are related to neoplastic formation, but there have been no detailed clinical reports of ALT associated with MD. Case Presentation. A 73‐year‐old woman with a diagnosis of limb‐girdle MD visited our department for recurrence of a huge tumor in her left thigh. She had undergone resection of a lipoma at the same site more than 20 years earlier. Imaging studies revealed a lipomatous tumor in her left thigh. We performed marginal resection including the adjacent muscles. Histological diagnosis was atypical lipomatous tumor. The postoperative course was uneventful, with no recurrence at 36 months of follow‐up. Conclusion. We encountered a huge atypical tumor in a patient with MD. This is the first detailed report to describe an association between ALT and MD. We hypothesize that degenerative changes occurring in adipose tissue during muscle atrophy can cause lipomatous neoplasms and moreover that the mutation of MD‐related genes may lead to the proliferation of tumor cells or to malignancy.
- Open Access
- 24 August 2014
- Published by Wiley in Case Reports in Orthopedics
- Vol. 2014, 1-4
Osteomyelitis Caused byCandida glabratain the Distal Phalanx
Osteomyelitis caused byCandida glabratais rare and its optimal treatment is unknown. Here we report a case of osteomyelitis caused byC. glabratain the distal phalanx in a 54-year-old woman. Despite partial resection of the nail and administering a 1-month course of antibiotics for paronychia, the local swelling remained and an osteolytic lesion was found.C. glabrataosteomyelitis of the distal phalanx was later diagnosed after curettage. Thereafter, the patient was treated with antifungal agents for 3 months. The infection eventually resolved, and radiological healing of the osteolytic lesion was achieved. Antifungal susceptibility testing should be performed in the case of osteomyelitis caused by nonalbicans Candida species, due to their resistance to fluconazole.
- 24 August 2014
- Published by Wiley in Case Reports in Orthopedics
- Vol. 2014, 1-4
Open AccessOsteomyelitis Caused byCandida glabratain the Distal Phalanx
Osteomyelitis caused byCandida glabratais rare and its optimal treatment is unknown. Here we report a case of osteomyelitis caused byC. glabratain the distal phalanx in a 54-year-old woman. Despite partial resection of the nail and administering a 1-month course of antibiotics for paronychia, the local swelling remained and an osteolytic lesion was found.C. glabrataosteomyelitis of the distal phalanx was later diagnosed after curettage. Thereafter, the patient was treated with antifungal agents for 3 months. The infection eventually resolved, and radiological healing of the osteolytic lesion was achieved. Antifungal susceptibility testing should be performed in the case of osteomyelitis caused by nonalbicans Candida species, due to their resistance to fluconazole.